CDH13 and breast carcinoma: The pCR rates observed in T-cadherin- and T-cadherin+, CK5/6− and CK5/6+, EGFR− and EGFR+, and p53− and p53+ breast cancer patients were 45.2% (n=1) vs 7.4% (n=1), 40% (n=2) vs 25.6% (n=2), 45.5% (n=1) vs 28.1% (n=1), and 33.3% (n=1) vs 27.3% (n=1), respectively.